This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
by Zacks Equity Research
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
HALONegative Net Change JNJNegative Net Change ARGXNegative Net Change HOWLNegative Net Change
biotechs
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
by Ahan Chakraborty
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
NVONegative Net Change LLYNegative Net Change ALTNegative Net Change MDGLNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
by Zacks Equity Research
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
INSMNegative Net Change VKTXNegative Net Change ACIUNegative Net Change
biotechs medical
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
by Zacks Equity Research
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
PCRXPositive Net Change ALNYPositive Net Change ALDXNegative Net Change ACIUNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
by Sundeep Ganoria
Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.
VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
by Zacks Equity Research
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
NVSNegative Net Change IONSNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
by Zacks Equity Research
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
RAREPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
PGENPositive Net Change MRKNegative Net Change INONegative Net Change
biotechs
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
by Zacks Equity Research
NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
NVONegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting
by Zacks Equity Research
LLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.
LLYNegative Net Change AZNNegative Net Change JNJNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals